Increase Development and Decrease Use! Innovation Controversies Caused by Antimicrobial Resistance

  • Alexandra Waluszewski
  • Enrico Baraldi
  • Francesco Ciabuschi


In Chapter 12, Waluszewski, Baraldi and Ciabuschi examine the issue of antimicrobial resistance which is challenging public health worldwide and is bound to impose a considerable economic burden on society. Resistant pathogens are estimated to cause over 700,000 deaths annually, while at the same time, infectious diseases treatable with existing antibiotics continue to cause more than five million deaths every year among poor people in low- and middle-income regions that cannot access antibiotics. This chapter pinpoints the changes necessary to address antimicrobial resistance in terms of new product development and changed usage patterns. The chapter also discusses the theoretical and methodological requirements and the need for a context-specific analysis of the development, production and settings in which antibiotics are used.


  1. Baraldi, E. (2003). When information technology faces resource interaction: Using IT tools to handle products at IKEA and edsbyn. Doctoral thesis, Department of Business Studies, Uppsala University.Google Scholar
  2. Baraldi, E., Ciabuschi, F., Leach, R., Morel, C. M., & Waluszewski, A. (2016). Exploring the obstacles to implementing economic mechanisms to stimulate antibiotic research and development a multi-actor and system-level analysis. American Journal of Law & Medicine, 42(2-3), 451–486.CrossRefGoogle Scholar
  3. Baraldi, E., Gregori, G. L., & Perna, A. (2011). Network evolution and the embedding of complex technical solutions: The case of the Leaf House network. Industrial Marketing Management, 40(6), 838–852.CrossRefGoogle Scholar
  4. Baraldi, E., Gressetvold, E., & Harrison, D. (2012). Resource interaction in inter-organizational networks: Foundations, comparison, and a research agenda. Journal of Business Research, 65(2), 266–276.CrossRefGoogle Scholar
  5. Barlam, T. F., & Gupta, K. (2015). Antibiotic resistance spreads across borders. The Journal of Law, Medicine and Ethics, 43(2), Symposium Articles Antimicrobial Resistance, 12–16.CrossRefGoogle Scholar
  6. Boucher, H. W., Talbot, G. H., Bradley, J. S. et al. (2009). Bad bugs, no drugs: No ESKAPE! an update from the infectious diseases society of America. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 48, 1–12.CrossRefGoogle Scholar
  7. Buckley, P. J. (ed.) (2011). Globalization and the global factory. Cheltenham: Edward Elgar.Google Scholar
  8. Burke, P. (1992). History and social theory. Ithaca: Cornell University Press.Google Scholar
  9. Callon, M. (ed.) (1998). The laws of the markets. London: Blackwell Publishers.Google Scholar
  10. Cars, O. (2014). Securing access to effective antibiotics for current and future generations. Whose responsibility? Uppsala Journal of Medical Sciences, 119, 209–214.CrossRefGoogle Scholar
  11. Ciabuschi, F., Holm, U., & Martín Martín, O. (2014). Dual embeddedness, influence and performance of innovating subsidiaries in the multinational corporation. International Business Review, 23, 897–909.CrossRefGoogle Scholar
  12. Daulaire, N., Bang, A., Tomson, J., Kalyango, J. N., & Cars, O. (2015). Universal access to effective antimicrobials: An essential feature of global collective action against antimicrobial resistance. The Journal of Law, Medicine and Ethics, 43(2), Symposium Articles Antimicrobial Resistance, 17–22.CrossRefGoogle Scholar
  13. David, P. (1985). Clio and the economics of QWERTY. The American Economic Review, 75(2), 332–337.Google Scholar
  14. Eklund, M. (2007). Adoption of the Innovation System Concept in Sweden. Doctoral dissertation. Uppsala Studies in Economic History, 81.Google Scholar
  15. Fleming, A. (1945). Penicillin. Nobel Lecture, December 11, 1945. Retrieved from: Accessed 27 Jul 2015
  16. Fontana, A., & Frey, J. (1994). The art of science. In N. Denzin (ed.), The handbook of qualitative research (pp. 361–376). Thousand Oaks: Sage.Google Scholar
  17. Forsgren, M., Holm, U., & Johanson, J. (2007). Managing the embedded multinational: A business network view. Cheltenham: Edward Elgar Publishing.Google Scholar
  18. Gustavsson, M. (2013). Methodomania. In S. Rider, Y. Hasselberg, & A. Waluszewski (eds.), Transformations in research, higher education and the academic market. The breakdown of scientific thought (pp. 150–170). Dordrecht: Springer Science & Business Media.Google Scholar
  19. Håkansson, H. (ed.) (1982). International marketing and purchasing of industrial goods – An interaction approach. New York: Wiley.Google Scholar
  20. Håkansson, H., Ford, D., Gadde, L.-E., Snehota, I., & Waluszewski, A. (2009). Business in networks. Chichester: Wiley.Google Scholar
  21. Håkansson, H., & Snehota, I. (eds.) (1995). Developing relationships in business networks’. London: International Thomson.Google Scholar
  22. Håkansson, H., & Waluszewski, A. (2002). Managing technological development. IKEA, the environment and technology. London: Routledge.CrossRefGoogle Scholar
  23. Håkansson, H., & Waluszewski, A. (2007). Interaction: The only means to create use. In H. Håkansson & A. Waluszewski (eds.), Knowledge and innovation in business and industry. The importance of using others (pp. 147–167). London: Routledge.Google Scholar
  24. Håkansson, H., & Waluszewski, A. (2016). Methodomania? On the methodological and theoretical challenges of IMP business research. The IMP Journal, 10(3): 443–463.CrossRefGoogle Scholar
  25. Harrison, D., & Waluszewski, A. (2008). The development of a user network as a way to re-launch an unwanted product. Research Policy, 37(1), 115–130.CrossRefGoogle Scholar
  26. Hoffman, J., & Outterson, K. (2015). What will It take to address the global threat of antibiotic resistance?. The Journal of Law, Medicine and Ethics, 43(2), Symposium Articles Antimicrobial Resistance, 6–11.CrossRefGoogle Scholar
  27. Hughes, T. P. (1983). Networks of power: Electrification in western society (1880–1930). Baltimore: John Hopkins University Press.Google Scholar
  28. Hughes, T. P. (1994). Beyond the economics of technology. In O. Granstrand (ed.), Economics of technology. Amsterdam: Elsevier Science Publ.Google Scholar
  29. Kinch, M. S., Patridge, E., Plummer, M., & Hoyer, D. (2014). An analysis of FDA-approved drugs for infectious disease: Antibacterial agents. Drug Discovery Today, 19(9), 1283–1287.CrossRefGoogle Scholar
  30. Latour, B. (1996). Aramis, or the love of technology. Cambridge: Harvard University Press.Google Scholar
  31. Law, J. (1992). Notes on the theory of actor network: Ordering, strategy and heterogeneity. System Practice, 5(4), 379–393.CrossRefGoogle Scholar
  32. Lundvall, B-Å. (1992). Introduction. In Lundvall (ed.), National systems of innovation: Towards a theory of innovation and interactive Learning. London: Pinter.Google Scholar
  33. Marglin, S. A. (2008). The dismal science: How thinking like an economist undermines community. Cambridge, MA: Harvard University.Google Scholar
  34. Maxwell, D., & Van Der Vorst, R. (2002). Developing sustainable products and services. Journal of Cleaner Production, 11, 883–895.CrossRefGoogle Scholar
  35. Merton, R. K., Fiske, M., & Kendall, P. L. (1956). The focused interview. Glencoe: Free Press.Google Scholar
  36. Mirowski, P. (2011). Science mart. Privatizing American science. Cambridge, MA: Harvard University Press.CrossRefGoogle Scholar
  37. Mossialos, E., Morel, C. M., Edwards, S., Berenson, J., Gemmill-Toyama, M., & Brogan, D. (2010). Policies and incentives for promoting innovation in antibiotic research. Copenhagen: World Health Organization.Google Scholar
  38. Nathan, C., & Cars, O. (2014). Antibiotic resistance — problems, progress, and prospects. New England Journal of Medicine, 371, 1761–1763.CrossRefGoogle Scholar
  39. O’Neill, J., ed (2015). Tackling drug-restistant infections globally. Final report and recommendations. The review on antimicrobial resistance chaired by Jim O Neill. London: Welcome Trust and UK Government.Google Scholar
  40. Outterson, K. (2014). New business models for sustainable antibiotics. London: Chatham House, Center on Global Health Security Working Group Papers.Google Scholar
  41. Outterson, K., Powers, J. H., Daniel, G. W., & McClellan, M. B. (2015). Repairing the broken market for antibiotic innovation. Health Affairs, 34(2), 277–285.CrossRefGoogle Scholar
  42. Rider, S., Waluszewski, A. (2015). Crowding out Knowledge: Efficiency, Innovation and Higher Education. In Michael Peters, João M. Paraskeva, Tina Besley, (eds.), The Global Financial Crisis and Educational Restructuring (Global Studies in Education) (pp. 235–248). New York: Peter Lang.Google Scholar
  43. Penrose, E. T. (1959). The theory of the growth of the firm. New York: Oxford University Press.Google Scholar
  44. Rosenberg, N. (1982). Inside the black box: Technology and economics. Cambridge: Cambridge University Press.Google Scholar
  45. Rosenberg, N. (1994). Exploring the black box: Technology, economics, history. Cambridge: Cambridge University Press.CrossRefGoogle Scholar
  46. So, A. D., Ruiz-Esparza, Q., Gupta, N., & Cars, O. (2012). 3Rs for innovating novel antibiotics: Sharing resources, risks, and rewards. The BMJ, 344, e1782.CrossRefGoogle Scholar
  47. Srivastava, S. K. (2007). Green supply chain management: A state-of-the-art literature review. International Journal of Management Reviews, 9(1), 53–80.CrossRefGoogle Scholar
  48. Strömsten, T., & Waluszewski, A. (2012). Governance and resource interaction in networks. The role of venture capital in a biotech start-up. Journal of Business Research, 65, 232–244.CrossRefGoogle Scholar
  49. Theuretzbacher, U. (2009). Future antibiotics scenarios: is the tide starting to turn?. International journal of Antimicrobial Agents, 34, 15–20.CrossRefGoogle Scholar
  50. Van De Ven, A., Polley, D., Garud, R., & Venkataraman, S. (1999). The innovation journey. New York, Oxford: Oxford University Press.Google Scholar
  51. Von Hippel, E. (1978). Successful industrial products from customer ideas – Presentation of a new customer-active paradigm with evidence and implications. Journal of Marketing, 42(1), 39–49.CrossRefGoogle Scholar
  52. Von Hippel, E. (1986). Lead users: A source of novel product concepts. Management Science, 32(7), 791–805.CrossRefGoogle Scholar
  53. Von Hippel, E. (1988). The sources of innovation. New York: Oxford University Press.Google Scholar
  54. Waluszewski, A., & Håkansson, H. (2007). Economic use of Knowledge. In Håkansson, H., Waluszewski, A, (eds), Knowledge and innovation in business and Industry. The importance of using others (pp. 1–27). London: Routledge.Google Scholar

Copyright information

© The Author(s) 2018

Authors and Affiliations

  • Alexandra Waluszewski
    • 1
  • Enrico Baraldi
    • 2
  • Francesco Ciabuschi
    • 3
  1. 1.Department of Economic History, Science and Technology Studies CentreUppsala UniversityUppsalaSweden
  2. 2.Department of Industrial Engineering & ManagementUppsala UniversityUppsalaSweden
  3. 3.Department of Business StudiesUppsala UniversityUppsalaSweden

Personalised recommendations